載入...
Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
BACKGROUND: Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PC...
Na minha lista:
| 發表在: | Lipids Health Dis |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7216641/ https://ncbi.nlm.nih.gov/pubmed/32393252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-020-01280-0 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|